129 Xenon Imaging in Patients Treated With Sotatercept

Phase 2

Not yet recruiting

• Conditions: Pulmonary Hypertension; Pulmonary Arterial Hypertension
• Interventions: Drug: 129Xe Hyperpolarized

• Registration Number: NCT06351345
• Lead Sponsor: Bastiaan Driehuys

Brief Summary

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Detailed Description

The researchers hypothesize that 129Xe MRI/MRS biomarker signatures of pulmonary vascular remodeling will predict short- and long-term response and efficacy to PAH patients who are receiving sotatercept as clinical standard-of-care. At baseline (prior to the treatment with sotatercept), 3, and 12 months of follow-up, the research team will perform 129Xe MRI/MRS scans. 129Xe MRI/MRS metrics, including: (1) 129Xe MRI ventilation defect (reflecting gas exchange abnormalities), (2)129Xe MRI RBC defect percentage (reflecting pulmonary capillary blood volume), (3) 129Xe MRI membrane uptake percentage (reflecting lung interstitial wall thick-ness and inflammation), and (4) 129Xe MRS oscillation amplitude (reflecting degree of pre/post-capillary PH) as well as standard-of-care assessments including labs, echocardiography, NTproBNP and 6MWD will be acquired at each visit. The investigators expect that 129Xe MRI/MRS biomarker signatures will improve prediction of treatment response and clinical outcomes (hospitalizations and death) compared to standard risk assessment with functional class, 6MWD, and NTproBNP.

This study would allow an assessment of sotatercept's role in promoting pulmonary vascular reverse remodeling. It could also improve outcome assessment in clinical trials to a biomarker that is more accurate and precise, thus allowing greater reliability in assessment of treatment effect and allowing smaller clinical trial size. Lastly, three-dimensional functional lung imaging could provide greater individualized assessment of lung function and tailoring of therapy, thus optimizing precision and personalized medicine.

PAH is characterized by obstructive vasculopathy of the pulmonary arterioles that results in right heart failure and death. The pulmonary vascular remodeling in PAH includes neointimal proliferation, medial hypertrophy, plexiform arteriopathy, and fibrosis; these changes can also differ between these subtypes. This results in specific changes in cardiac and pulmonary physiology, most notably: (1) an increase in the pulmonary vascular resistance (PVR) through the blood vessels due to their obstruction; and (2) a decrease in sur-face area and capillary blood volume for gas exchange through disruption of the normal capillary-alveolar interface with a decrease in the diffusion limit for carbon monoxide (DLCO). The increase in PVR results in increased afterload on the right heart, resulting in right ventricular (RV) dysfunction and failure. Similarly, gas exchange abnormalities contribute to decreased ventilatory efficiency and exercise limitation. Current treatments, which target the prostacyclin, endothelin-1, or nitric oxide pathways, slow disease progression. However, these drugs are thought to act largely through vasodilation, and not through remodeling. For that reason, the 5-year survival rate in PAH is still only approximately 60%, highlighting the need for therapies targeting pulmonary vascular remodeling pathways.

Study Timeline

• Study First Submitted: 2024-04-02
• Study First Submitted QC: 2024-04-02
• Study First Posted: 2024-04-08
• Status Verified: 2025-01
• Last Update Submitted: 2025-05-15
• Last Update Posted: 2025-05-20
• Study Start: 2025-07-01
• Primary Completion: 2026-08-01
• Study Completion: 2026-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Outpatients of either gender, Age 18-75
2. Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH)
3. Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
4. On a stable dose of background PAH therapy for > 90 days prior to study enrollment
5. Women of childbearing potential must have a negative urine pregnancy test before MRI

Exclusion Criteria

1. Moderate to severe heart disease (LVEF < 45%, Severe LV hypertrophy, Moderate to severe valvular disease)
2. Chronic thromboembolic disease
3. PH due to schistosomiasis
4. Active cancer
5. Sickle cell anemia
6. Prisoners and pregnant women will not be approached for the study
7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)
8. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pulmonary Arterial Hypertension Patients Receving Sotatercept	129Xe Hyperpolarized	PAH patients receiving sotatercept as treatment for their PAH

Primary Outcome Measures

Name	Time	Method
Change in Xenon MRI Red Blood Cell (RBC) percentage	baseline, 3,and 12 months
Change in cardiogenic oscillation amplitudes	baseline, 3, and 12 months

Trial Locations

Locations (1)

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States